Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 4/2015

01-12-2015 | Gynecologic Oncology (R Salani, Section Editor)

The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions

Authors: Brittany Lees, Charles A. Leath III

Published in: Current Obstetrics and Gynecology Reports | Issue 4/2015

Login to get access

Abstract

Diabetes mellitus has reached epidemic proportions in both the USA and worldwide with most authorities reporting a doubling in the prevalence of diabetes over the last 20–30 years. While this epidemic is closely tied to obesity, diabetes mellitus presents potential clinical challenges over and above that observed with obesity alone. From a women’s healthcare prospective, this rise in diabetes may impact a woman’s health across her lifespan. More specifically, diabetes impacts not only pregnancy as well as other medical conditions but increases the risk for the development of various malignancies. From a gynecologic cancer standpoint, diabetes is most closely associated with endometrial adenocarcinomas, although increasing attention is being placed upon diabetes and ovarian cancer. Attention is also being placed on the potential role of metformin and its impact on outcomes in diabetics with cancer, as well as a potential preventative and/or adjunctive therapy for gynecologic cancer.
Literature
1.
Organization W.H. Global status report on noncommunicable diseases 2014. Geneza: World Health Organization; 2014.
2.
Zimmet PZ et al. Diabetes: a 21st century challenge. Lancet Diabet Endocrinol. 2014;2(1):56–64.CrossRef
3.
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2012;8(4):228–36.CrossRef
4.
5.•
Romero IL et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012;119(1):61–7. Although containing a limited number of diabetics receiving metformin, 16 of 44 diabetic patients, the marked difference in outcomes when compared to both non-diabetics as well as diabetics not on metformin was quite provocative.PubMedCentralCrossRefPubMed
6.•
Shah MM et al. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–7. More recent series that again demonstrates inferior ovarian cancer survival for diabetics, with generally similar clinical covariates, when compared to non-diabetics.PubMedCentralCrossRefPubMed
7.
Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol. 2011;121(1):106–11.CrossRefPubMed
8.
9.
10.
Friberg E et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.CrossRefPubMed
11.
Liu X, et al. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015.
12.
13.
Stocks T, et al. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol. 2015.
14.
Trabert B et al. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev. 2015;24(1):261–7.CrossRefPubMed
15.
Esposito K et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28–36.CrossRefPubMed
16.
Zanders MM et al. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas. 2013;74(1):37–43.CrossRefPubMed
17.
18.
Quinn BJ et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24(9):469–80.CrossRefPubMed
19.
20.
21.
Currie CJ et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35(2):299–304.PubMedCentralCrossRefPubMed
22.
23.
Ko EM et al. Metformin and the risk of endometrial cancer: a population-based cohort study. Gynecol Oncol. 2015;136(2):341–7.CrossRefPubMed
24.
Tabrizi AD et al. Antiproliferative effect of metformin on the endometrium—a clinical trial. Asian Pac J Cancer Prev. 2014;15(23):10067–70.CrossRefPubMed
25.
Cantrell LA et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92–8.PubMedCentralCrossRefPubMed
26.
Mitsuhashi A et al. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014;120(19):2986–95.CrossRefPubMed
27.
Hanna RK et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012;125(2):458–69.PubMedCentralCrossRefPubMed
28.
Uehara T et al. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncol Rep. 2015;33(2):744–50.PubMed
29.
Morgan Jr RJ et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(10):1199–209.PubMed
30.
Tewari D et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6.CrossRefPubMed
31.
Landrum LM et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130(1):12–8.CrossRefPubMed
32.
Olsen CM et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43(4):690–709.CrossRefPubMed
33.
Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5(7):901–10.CrossRef
34.
Yang HS et al. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011;21(9):1525–32.CrossRefPubMed
35.
Collaborative Group on Epidemiological Studies of Ovarian, C. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9(4):e1001200.CrossRef
36.
Ma X et al. Anthropometric measures and epithelial ovarian cancer risk among Chinese women: results from the Shanghai Women’s Health Study. Br J Cancer. 2013;109(3):751–5.PubMedCentralCrossRefPubMed
37.
Kalli KR, Conover CA. The insulin-like growth factor/insulin system in epithelial ovarian cancer. Front Biosci. 2003;8:d714–22.CrossRefPubMed
38.
Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14(1):98–107.PubMed
39.
40.
Joung KH, Jeong JW, Ku BJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int. 2015;2015:920618.PubMedCentralCrossRefPubMed
41.
Nagle CM, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015.
42.
Nagle CM et al. Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer. Ann Oncol. 2011;22(6):1332–8.CrossRefPubMed
43.
Lee JY et al. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2013;23(3):402–12.CrossRefPubMed
44.
Febbraro T, Lengyel E, Romero IL. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014;135(3):614–21.CrossRefPubMed
45.
Lengyel E et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015;212(4):479. e1-479 e10.CrossRefPubMed
46.
Bodmer M et al. Use of metformin and the risk of ovarian cancer: a case–control analysis. Gynecol Oncol. 2011;123(2):200–4.CrossRefPubMed
47.•
Kumar S et al. Metformin intake is associated with better survival in ovarian cancer: a case–control study. Cancer. 2013;119(3):555–62. Well designed case–control study again noting differential impacts on survival in women utilizing metformin with superior survival in those on metformin therapy.PubMedCentralCrossRefPubMed
Metadata
Title
The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions
Authors
Brittany Lees
Charles A. Leath III
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 4/2015
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-015-0127-x

Other articles of this Issue 4/2015

Current Obstetrics and Gynecology Reports 4/2015 Go to the issue

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Concomitant Infection of HIV and HPV: What Are the Consequences?

Gynecologic Oncology (R Salani, Section Editor)

Nutrition in Gynecologic Cancer

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Human Papillomavirus (HPV) Testing for Secondary Prevention of Cervical Cancer

Gynecologic Oncology (R Salani, Section Editor)

Tobacco Use and Outcomes in Gynecologic Malignancy

Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)

Immunology of HPV Infection

Gynecologic Oncology (R Salani, Section Editor)

Obesity Education Strategies for Cancer Prevention in Women’s Health